Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed through laboratory testing of tissue samples.
- People who received chemotherapy (using either a regimen called FOLFIRINOX or a combination of Gemcitabine and nab-paclitaxel) before surgery.
- People for whom blood plasma samples taken before treatment are available for testing.
- People who went through surgery with the goal of fully removing the cancer (classified as R0 or R1 removal).
Who may not be able to join:
- People whose stored blood plasma samples are insufficient in quantity or too low in quality for the specific type of analysis the trial requires.
- People whose pancreatic cancer is a type other than adenocarcinoma.
- People who have, or had at the same time, another separate cancer diagnosis.
- People who received a chemotherapy regimen other than the two standard ones listed (FOLFIRINOX or Gemcitabine plus nab-paclitaxel).
- People who have an active inflammatory or autoimmune disease (a condition where the immune system attacks the body).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ajay Goel, PhD, City of Hope Medical Center
Phone: 626-218-3452
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathological Response Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.